Ezabenlimab, PD-1 antibody
Phase 1
Therapeutic Area: Oncology
Boehringer Ingelheim has made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers. We have developed a robust pipeline of homegrown and licensed/partnered clinical assets with a diverse range of mode of actions, including cancer cell-directed and immuno-oncology investigational therapies. It’s the smart combination of these approaches that may offer the greatest benefit for people living with cancer.
Ezabenlimab is a humanized programmed cell death 1 (PD-1)-targeting monoclonal antibody.
Immune/stromal modulators are part of our immuno-oncology strategy to boost the body’s immune response against the cancer.
This compound is under investigation, further information will be available soon.